NASDAQ:IMGN ImmunoGen (IMGN) Stock Forecast, Price & News $14.37 +0.20 (+1.41%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$14.10▼$14.5450-Day Range$3.69▼$14.5352-Week Range$3.10▼$14.91Volume3.85 million shsAverage Volume5.41 million shsMarket Capitalization$3.25 billionP/E RatioN/ADividend YieldN/APrice Target$13.71 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ImmunoGen MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside4.6% Downside$13.71 Price TargetShort InterestHealthy6.89% of Shares Sold ShortDividend StrengthN/ASustainability-0.53Upright™ Environmental ScoreNews Sentiment0.68Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.55) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector645th out of 983 stocksPharmaceutical Preparations Industry320th out of 486 stocks 1.4 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.71, ImmunoGen has a forecasted downside of 4.6% from its current price of $14.37.Amount of Analyst CoverageImmunoGen has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.89% of the outstanding shares of ImmunoGen have been sold short.Short Interest Ratio / Days to CoverImmunoGen has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmunoGen has recently decreased by 32.55%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreImmunoGen has received a 74.81% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for ImmunoGen is -0.53. Previous Next 3.2 News and Social Media Coverage News SentimentImmunoGen has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ImmunoGen this week, compared to 3 articles on an average week.Search InterestOnly 34 people have searched for IMGN on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat Follows20 people have added ImmunoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 122% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.07% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions89.13% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to grow in the coming year, from ($0.55) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -15.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -15.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoGen has a P/B Ratio of 26.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ImmunoGen (NASDAQ:IMGN) StockImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.Read More Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address IMGN Stock News HeadlinesMay 13, 2023 | marketbeat.comMarketBeat Week in Review – 5/8 - 5/12 (IMGN)Inflation, bank woes, interest rates, and the debt ceiling led to more of the new normal for equity markets. Here are some of this week's most popular articlesMay 8, 2023 | marketbeat.comImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drugJune 3, 2023 | Behind the Markets (Ad)⚡ 2,467% Return on Israeli Laser Company?This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.June 1, 2023 | fool.comImmunoGen (NASDAQ: IMGN)May 31, 2023 | americanbankingnews.comImmunoGen, Inc. (NASDAQ:IMGN) Receives $13.71 Consensus Price Target from AnalystsMay 24, 2023 | finance.yahoo.comImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare ConferenceMay 22, 2023 | finance.yahoo.comWhen Will ImmunoGen, Inc. (NASDAQ:IMGN) Breakeven?May 21, 2023 | americanbankingnews.comImmunoGen Sees Unusually High Options Volume (NASDAQ:IMGN)June 3, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 19, 2023 | finance.yahoo.comHere's Why You Should Add ImmunoGen (IMGN) to Your Portfolio NowMay 18, 2023 | americanbankingnews.comShort Interest in ImmunoGen, Inc. (NASDAQ:IMGN) Decreases By 5.8%May 14, 2023 | americanbankingnews.comSVB Leerink Analysts Increase Earnings Estimates for ImmunoGen, Inc. (NASDAQ:IMGN)May 12, 2023 | seekingalpha.comImmunoGen: Making A Successful ComebackMay 12, 2023 | msn.comShould You Buy ImmunoGen (IMGN) After Golden Cross?May 10, 2023 | msn.com2 Regulatory Submissions Of ELAHERE In 2023 Make ImmunoGen A Must WatchMay 10, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for ImmunoGen, Inc. (NASDAQ:IMGN) Raised by AnalystMay 8, 2023 | americanbankingnews.comImmunoGen, Inc. (NASDAQ:IMGN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMay 5, 2023 | americanbankingnews.comImmunoGen (NASDAQ:IMGN) Rating Increased to Overweight at Piper SandlerMay 5, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for ImmunoGen, Inc. Raised by Analyst (NASDAQ:IMGN)May 5, 2023 | finance.yahoo.comImmunoGen Announces Pricing of Upsized Public Offering of Common StockMay 5, 2023 | finance.yahoo.comImmunoGen Announces Pricing of Upsized Public Offering of Common StockMay 4, 2023 | seekingalpha.comImmunoGen: Shares Take Flight On Ovarian Cancer Survival Data - What Happens Next?May 4, 2023 | seekingalpha.comImmunoGen's Elahere Breakthrough Offers Hope For Patients And Investors AlikeMay 4, 2023 | americanbankingnews.comImmunoGen (NASDAQ:IMGN) Raised to Hold at StockNews.comMay 3, 2023 | finance.yahoo.comGood News for Patients Is Lifting These 2 Biopharma StocksMay 3, 2023 | finance.yahoo.comWall Street Analysts See a 101.92% Upside in ImmunoGen (IMGN): Can the Stock Really Move This High?May 3, 2023 | finance.yahoo.comImmunoGen Touts Additional Positive Data From Ovarian Cancer Drug, Seeks Expanded Use Approval, Stock SoarsSee More Headlines IMGN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMGN Company Calendar Last Earnings4/28/2023Today6/03/2023Next Earnings (Estimated)8/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMGN CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees106Year Founded1981Price Target and Rating Average Stock Price Forecast$13.71 High Stock Price Forecast$22.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside-4.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-222,930,000.00 Net Margins-198.88% Pretax Margin-197.87% Return on Equity-135.94% Return on Assets-67.63% Debt Debt-to-Equity RatioN/A Current Ratio2.40 Quick Ratio2.39 Sales & Book Value Annual Sales$108.78 million Price / Sales29.86 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book26.61Miscellaneous Outstanding Shares226,070,000Free Float214,608,000Market Cap$3.25 billion OptionableOptionable Beta0.88 Social Links Key ExecutivesMark Joseph EnyedyPresident, Chief Executive Officer & DirectorRenee LentiniVP-Finance, Chief Financial & Accounting OfficerAnna BerkenblitChief Medical Officer & Senior Vice PresidentMichael J. VasconcellesEVP-Research, Development & Medical AffairsRobert HerbstVice President-Technical OperationsKey CompetitorsAmicus TherapeuticsNASDAQ:FOLDGeronNASDAQ:GERNIronwood PharmaceuticalsNASDAQ:IRWDDynavax TechnologiesNASDAQ:DVAXAlkermesNASDAQ:ALKSView All CompetitorsInstitutional OwnershipProShare Advisors LLCSold 5,308 shares on 5/26/2023Ownership: 0.018%Putnam Investments LLCBought 29,841 shares on 5/22/2023Ownership: 0.509%Ameriprise Financial Inc.Sold 882 shares on 5/22/2023Ownership: 0.127%New York State Common Retirement FundBought 23,084 shares on 5/18/2023Ownership: 0.107%JPMorgan Chase & Co.Bought 16,400 shares on 5/18/2023Ownership: 0.000%View All Institutional Transactions IMGN Stock - Frequently Asked Questions Should I buy or sell ImmunoGen stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares. View IMGN analyst ratings or view top-rated stocks. What is ImmunoGen's stock price forecast for 2023? 5 Wall Street research analysts have issued twelve-month target prices for ImmunoGen's stock. Their IMGN share price forecasts range from $9.00 to $22.00. On average, they expect the company's share price to reach $13.71 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts. How have IMGN shares performed in 2023? ImmunoGen's stock was trading at $4.96 at the start of the year. Since then, IMGN stock has increased by 189.7% and is now trading at $14.37. View the best growth stocks for 2023 here. Are investors shorting ImmunoGen? ImmunoGen saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 15,580,000 shares, a decline of 32.6% from the April 30th total of 23,100,000 shares. Based on an average daily trading volume, of 6,540,000 shares, the days-to-cover ratio is currently 2.4 days. View ImmunoGen's Short Interest. When is ImmunoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023. View our IMGN earnings forecast. How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings results on Friday, April, 28th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.09. The biotechnology company earned $49.90 million during the quarter, compared to the consensus estimate of $21.63 million. ImmunoGen had a negative trailing twelve-month return on equity of 135.94% and a negative net margin of 198.88%. The firm's revenue for the quarter was up 31.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.10) earnings per share. What ETFs hold ImmunoGen's stock? ETFs with the largest weight of ImmunoGen (NASDAQ:IMGN) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC). What guidance has ImmunoGen issued on next quarter's earnings? ImmunoGen issued an update on its FY 2023 earnings guidance on Friday, April, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $45.00 million-$50.00 million, compared to the consensus revenue estimate of $108.34 million. What is Mark J. Enyedy's approval rating as ImmunoGen's CEO? 16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX). What is ImmunoGen's stock symbol? ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN." Who are ImmunoGen's major shareholders? ImmunoGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.96%), State Street Corp (7.55%), Wellington Management Group LLP (4.36%), Maverick Capital Ltd. (3.48%), Geode Capital Management LLC (1.79%) and Artisan Partners Limited Partnership (1.41%). View institutional ownership trends. How do I buy shares of ImmunoGen? Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ImmunoGen's stock price today? One share of IMGN stock can currently be purchased for approximately $14.37. How much money does ImmunoGen make? ImmunoGen (NASDAQ:IMGN) has a market capitalization of $3.25 billion and generates $108.78 million in revenue each year. The biotechnology company earns $-222,930,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. How many employees does ImmunoGen have? The company employs 106 workers across the globe. Does ImmunoGen have any subsidiaries? The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..Read More How can I contact ImmunoGen? ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611. This page (NASDAQ:IMGN) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.